Detalhe da pesquisa
1.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Lancet Infect Dis
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38552653
2.
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
Vaccine
; 41(51): 7587-7597, 2023 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993355